IMPT-314
Phase 1- Indications
- Large B-cell lymphoma, Systemic lupus erythematosus, Lupus nephritis
Company intelligence / Profile preview
ImmPACT Bio
West Hills, California, United Statesimmpact-bio.com ↗
- Ownership
- Private
- Employees
- ~200
- Development stage
- Phase 1
01
Overview
The company provided an optimistic update on a Phase I clinical study evaluating its CD19-CD20 bi-specific Chimeric Antigen Receptor T-cell (CAR-T) therapy. They are also developing IMPT-514, a CD19/CD20 bispecific CAR T-cell treatment for systemic lupus erythematosus and refractory lupus nephritis[4][2].
- Therapeutic areas
- OncologyImmunology
- Modalities
- CAR T-cell therapiesBispecific Chimeric Antigen Receptor (CAR) T cells
- Industry
- Biotech
02
Drug pipeline
2 assets1 more asset in the full pipeline.
Request access →Beyond the preview
Go deeper on ImmPACT Bio.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ImmPACT Bio.